Cascades Analytics with Tanya Ramey (Altaïr, Former Usona, Pfizer, NIDA)

Tanya Ramey shares professional experiences transitioning from traditional pharmaceutical development at companies like Pfizer to the field of psychedelic medicine. A discussion ensues regarding the clinical development of compounds like psilocybin and 5-MeO-DMT, highlighting the technical challenges in designing trials for psychiatric indications. Ramey addresses the distinctions between traditional antidepressant research and psychedelic clinical trials, focusing on outcome measures and study design. The conversation examines how substances like psilocybin could potentially treat major depressive disorder and PTSD by moving beyond simple symptom management. Ramey emphasizes the need for better trial designs that account for heterogeneous responses and durable therapeutic effects, suggesting that standard frameworks like DSM criteria may need refinement for these novel treatments.